![]() |
Name |
Xylaropyrone B
|
Molecular Formula | C12H18O4 | |
IUPAC Name* |
5-(hydroxymethyl)-2-[(1S,3R)-1-hydroxy-3-methylpentyl]pyran-4-one
|
|
SMILES |
CC[C@@H](C)C[C@@H](C1=CC(=O)C(=CO1)CO)O
|
|
InChI |
InChI=1S/C12H18O4/c1-3-8(2)4-11(15)12-5-10(14)9(6-13)7-16-12/h5,7-8,11,13,15H,3-4,6H2,1-2H3/t8-,11+/m1/s1
|
|
InChIKey |
VWXRIXPWCVYPKR-KCJUWKMLSA-N
|
|
Synonyms |
Xylaropyrone B
|
|
CAS | NA | |
PubChem CID | 139591696 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 226.27 | ALogp: | 1.2 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.807 |
Caco-2 Permeability: | -4.791 | MDCK Permeability: | 0.00000907 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.941 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.022 |
30% Bioavailability (F30%): | 0.59 |
Blood-Brain-Barrier Penetration (BBB): | 0.532 | Plasma Protein Binding (PPB): | 71.73% |
Volume Distribution (VD): | 0.586 | Fu: | 40.59% |
CYP1A2-inhibitor: | 0.203 | CYP1A2-substrate: | 0.561 |
CYP2C19-inhibitor: | 0.065 | CYP2C19-substrate: | 0.318 |
CYP2C9-inhibitor: | 0.094 | CYP2C9-substrate: | 0.235 |
CYP2D6-inhibitor: | 0.029 | CYP2D6-substrate: | 0.342 |
CYP3A4-inhibitor: | 0.018 | CYP3A4-substrate: | 0.249 |
Clearance (CL): | 8.739 | Half-life (T1/2): | 0.886 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.106 |
Drug-inuced Liver Injury (DILI): | 0.268 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.671 | Maximum Recommended Daily Dose: | 0.946 |
Skin Sensitization: | 0.154 | Carcinogencity: | 0.76 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.627 |
Respiratory Toxicity: | 0.282 |